Get a Trading Sidekick!

CytoSorbents Corporation, a development stage company, is engaged in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company develops its adsorbent polymer technology for various applications in the medical field, primarily to provide blood purification for acute and chronic health complications associated with blood toxicity. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications, including acute respiratory distress syndrome, severe burn injury, trauma, and pancreatitis; to prevent and treat organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and for the prevention and treatment of post-operative complications of cardiopulmonary bypass surgery. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.